Navigation Links
Data from Investigator-Sponsored Trial of Oncophage Cancer Vaccine,in Glioma Presented at American Association of Neurological,Surgeons Annual Meeting

rials. These risks and uncertainties include, among others, the risk that a small investigator-sponsored study in 12 patients is not representative of what will be shown in larger trials that could support registration; and the factors described under Factors That May Impact Future Results in the Management's Discussion and Analysis of Financial Condition and Results of Operations section of Antigenics' Annual Report on Form 10-K as filed with the Securities and Exchange Commission on March 16, 2007. Antigenics cautions investors not to place considerable reliance on the forward-looking statements contained in this press release. These statements speak only as of the date of this document, and Antigenics undertakes no obligation to update or revise the statements. All forward-looking statements are expressly qualified in their entirety by this cautionary statement. Antigenics' business is subject to substantial risks and uncertainties, including those identified above. When evaluating Antigenics' business and securities, investors should give careful consideration to these risks and uncertainties.

Contact

Antigenics Inc.
Sunny Uberoi, 917-443-3325
Media Relations
suberoi@antigenics.com
or
Robert Anstey, 800-962-2436
Investor Relations
ir@antigenics.com


'"/>




Page: 1 2 3 4

Related medicine technology :

1. Antisoma Announces Further Data From ASA404 Ovarian Cancer Trial
2. YM BioSciences Announces Secondary Efficacy and Safety Findings in Randomized Phase IIB Aerolef Trial
3. Halozyme Therapeutics Enhanze Technology Large Protein Molecule Therapeutic Clinical Trial Results Presented at the 34th Annual Meeting of the Controlled Release Society
4. AVI BioPharma Partner Cook Medical Announces Completion of Patient Enrollment for APPRAISAL Phase II Clinical Trial for Treatment of Cardiovascular Disease
5. Gene Therapy Eradicates Pancreatic Cancer in Preclinical Trial Targeting Systems Success in Mouse Model Reported in Cancer Cell
6. AM-Pharma Announces Positive Results of Phase IIa Clinical Trial with Alkaline Phosphatase For Ulcerative Colitis
7. Phase III Trial Results Show Superiority of Rivaroxaban over Enoxaparin for the Prevention of Venous Thromboembolism in Patients Undergoing Knee Replacement Surgery
8. Phase III Trial Results Show Superiority of Rivaroxaban over Enoxaparin for the Prevention of Venous Thromboembolism in Patients Undergoing Knee Replacement Surgery
9. TransPharma Medical Announces Positive Results of Phase I Clinical Trials for Transdermal Delivery of hPTH (1-34) for Osteoporosis Treatment
10. Pro-Pharmaceuticals Updates Progress of Clinical Trials & Davanat 505 (b)(2) Filings
11. MediGene Announces Cancer-Fighting Virus Shows Promise in Early Clinical Trial
Post Your Comments:
(Date:9/18/2014)... Sept. 18, 2014  ADM Tronics Unlimited, Inc. ... Ph.D. to its corporate Advisory Board for business ... at the Harvard Medical School and Visiting Professor ... received his Masters degree in Electronics Engineering and ... University of Bologna. After spending a year as ...
(Date:9/18/2014)... Sept. 18, 2014 MiMedx Group, Inc. ... processor and marketer of patent protected regenerative biomaterials ... today that it has entered into a distribution ... will provide its dehydrated human amnion/chorion membrane ("dHACM") ... exclusively on a private label basis. ...
(Date:9/18/2014)... and PLAINSBORO, N.J. , ... its support of the National Hemophilia Foundation,s (NHF) ... which provides support to people with hemophilia and ... psychosocial challenges that can impede disease management. The ... Communication With Your Provider About Pain , ...
Breaking Medicine Technology:ADM Tronics Appoints Gianluca DeNovi, Ph.D. To Advisory Board 2ADM Tronics Appoints Gianluca DeNovi, Ph.D. To Advisory Board 3MiMedx Signs Distribution Agreement With Zimmer 2MiMedx Signs Distribution Agreement With Zimmer 3Novo Nordisk Supports National Hemophilia Foundation Initiative for "Collaborating in Care" Disease Management Program 2Novo Nordisk Supports National Hemophilia Foundation Initiative for "Collaborating in Care" Disease Management Program 3
... survival,in the SPARC Phase 3 trial consistently demonstrate ... patients receiving,satraplatin. These analyses included prior Taxotere use,geographies, ... -- The two,major causes of progression in the ... were each associated with a 36%,reduction in relative ...
... co-primary endpoints, Wake After Sleep Onset and Total,Sleep Time, ... met at both doses - Evotec to host a,conference ... today , HAMBURG, Germany | OXFORD, England, June 4, ... top-line,results from its first phase II clinical trial of ...
Cached Medicine Technology:Additional New Data from Satraplatin SPARC Phase 3 Investigational,Trial Presented at ASCO Annual Meeting 2Additional New Data from Satraplatin SPARC Phase 3 Investigational,Trial Presented at ASCO Annual Meeting 3Additional New Data from Satraplatin SPARC Phase 3 Investigational,Trial Presented at ASCO Annual Meeting 4Additional New Data from Satraplatin SPARC Phase 3 Investigational,Trial Presented at ASCO Annual Meeting 5Additional New Data from Satraplatin SPARC Phase 3 Investigational,Trial Presented at ASCO Annual Meeting 6Additional New Data from Satraplatin SPARC Phase 3 Investigational,Trial Presented at ASCO Annual Meeting 7Evotec AG (DE) - Evotec Reports Positive Proof-of-Concept Top-Line,Results with ... 2Evotec AG (DE) - Evotec Reports Positive Proof-of-Concept Top-Line,Results with ... 3Evotec AG (DE) - Evotec Reports Positive Proof-of-Concept Top-Line,Results with ... 4
(Date:9/18/2014)... (PRWEB) September 18, 2014 It is that ... in health and wellness. Once again, Evensong Spa ... Week by offering three services at a special $50 rate ... managed by Marcus Hotels & Resorts , is the ... event encouraging Americans to embrace health and wellness by experiencing ...
(Date:9/18/2014)... Study after study has proven it true: exercise is ... Pennsylvania scientists suggests that exercise may have an added ... performed in a mouse model of melanoma, found that ... alone. , Joseph Libonati, an associate professor in ... of Innovative and Translational Nursing Research, was the senior ...
(Date:9/18/2014)... Lake City, UT (PRWEB) September 18, 2014 ... North America will be recognizing their shared fundraising impact ... on Thursday, Sept. 25. , The first-ever Dance Marathon ... more than $20 million projected to be raised by ... their community’s CMN Hospital. Donations generated through Dance Marathon ...
(Date:9/18/2014)... breeding grounds for microbes -- don,t worry, it,s a ... years, not all microbes are bad. Many active enzymes ... beneficial to humans as an important part of our ... , Candida albicans , an opportunistic yeast pathogen ... doesn,t damage our healthy personal ecosystem. However, when our ...
(Date:9/18/2014)... National Institutes of Health (NIH) recently awarded the first ... to the Los Angeles Biomedical Research Institute (LA BioMed) ... vaccine to protect patients from the healthcare-related infections, ... (MRSA). , The National Institute of Allergy and Infectious ... LA BioMed infectious disease specialists John E. Edwards, MD, ...
Breaking Medicine News(10 mins):Health News:Evensong Spa Celebrates Spa Week with $50 Services 2Health News:Evensong Spa Celebrates Spa Week with $50 Services 3Health News:Exercise boosts tumor-fighting ability of chemotherapy, Penn team finds 2Health News:250 Campuses Usher in School Year of Saving Kids’ Lives During First-Ever “Dance Marathon Day” on Sept. 25 2Health News:Everything in moderation: Micro-8 to study regulating pathogens in space 2Health News:Everything in moderation: Micro-8 to study regulating pathogens in space 3Health News:LA BioMed receives NIH grant to study vaccine for hospital-acquired infections 2
... law stipulates that the Department of Veterans Affairs has ... have earned by virtue of their service to our ... of Vietnam Veterans of America (VVA). "What is ... inform veterans -- and the healthcare community -- of ...
... N.J., May 19 Quest Diagnostics Incorporated (NYSE: ... and services, announced today that it has commenced a cash ... amount (the "Tender Cap") of its 5.125% Senior Notes due ... The terms and conditions of the tender offer are described ...
... free swim classes for Gainesville children age 6 months ... Sebastian Ferrero Foundation is partnering with ... Center to provide over 300 local children the opportunity ... Swim for Safety event is part of an ongoing initiative coordinated ...
... by Prof. Nils Brose of the Max Planck Institute for ... of the European Union, to study the role of synaptic ... teams is headed by Prof. Kobi Rosenblum of the University ... awarded a grant of 600,000 Euro. The topic of the ...
... 19 A new Deloitte study profiling the ... Canada and Germany was released today at the ... findings of the report, available at ... comparative effectiveness has the potential to improve care ...
... Health Equipment business sold in two separate transactions-- ... additional working capital to fund DailyMed(TM) growthINDIANAPOLIS, May ... KAD ), a leading provider of home ... Arcadia HealthCare(SM) brand, today announced the sale of ...
Cached Medicine News:Health News:VA Needs Legislative Push to Inform Veterans of Health Issues Connected to Military Service 2Health News:Quest Diagnostics Commences Cash Tender Offer for Up to $200 Million Aggregate Principal Amount of Certain of its Outstanding Notes 2Health News:Quest Diagnostics Commences Cash Tender Offer for Up to $200 Million Aggregate Principal Amount of Certain of its Outstanding Notes 3Health News:Quest Diagnostics Commences Cash Tender Offer for Up to $200 Million Aggregate Principal Amount of Certain of its Outstanding Notes 4Health News:Sebastian Ferrero Foundation Continues Support of Community Child Safety Programs 2Health News:Deloitte Comparative Effectiveness Study Evaluates Potential Savings Opportunities for U.S. Health Care System 2Health News:Deloitte Comparative Effectiveness Study Evaluates Potential Savings Opportunities for U.S. Health Care System 3Health News:Deloitte Comparative Effectiveness Study Evaluates Potential Savings Opportunities for U.S. Health Care System 4Health News:Deloitte Comparative Effectiveness Study Evaluates Potential Savings Opportunities for U.S. Health Care System 5Health News:Arcadia Resources Announces Sale of Non-Strategic Businesses 2Health News:Arcadia Resources Announces Sale of Non-Strategic Businesses 3Health News:Arcadia Resources Announces Sale of Non-Strategic Businesses 4
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
Medicine Products: